FDA Approves GlaxoSmithKline's Commit Lozenges

Commit Lozenge is a Nicotine Replacement Therapy produced by COPD International and manufactured by GlaxoSmithKline. Like its sibling products, Nicorette and the Nicoderm patch, the active ingredient is nicotine polacrilex. The Commit Lozenge comes in two strengths: 2mg and 4mg.

http://en.wikipedia.org/wiki/Commit_Lozenge